rGLP-1 protein

04/01/2015 - "Thus, albiglutide is an effective and generally well tolerated treatment option for patients with inadequately controlled type 2 diabetes. "
09/01/2014 - "The recent results from the HARMONY 3 and HARMONY 6 trials suggest that albiglutide is a safe and effective treatment option for patients with type 2 diabetes mellitus."
07/19/2021 - "We conducted qualitative focus groups and quantitative surveys as part of the EHR Ancillary Study, which is being conducted alongside the multicenter, global, Harmony Outcomes Trial comparing albiglutide to standard care for the prevention of cardiovascular events in type 2 diabetes. "
06/01/2019 - "Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus."
01/01/2018 - "Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics."

10/27/2018 - "We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. "
10/27/2018 - "We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. "
01/01/2023 - "The effect of albiglutide on reducing the composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular events) was consistent with or without SGLT2 inhibitors (P interaction = 0.70). "
03/01/2019 - "Moreover, semaglutide reduced non-fatal stroke and albiglutide reduced myocardial infarction, while extended-release exenatide reduced all-cause death; however, P value of significance for these outcomes should be considered nominal."
01/01/2023 - "Liraglutide, albiglutide, oral semaglutide and efpeglenatide, were not shown to reduce the number of strokes but did reduce major cardiovascular events. "

01/01/2011 - "Albiglutide reduced myocardial infarct size and improved cardiac function and energetics following myocardial I/R injury. "
10/27/2018 - "We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. "
10/27/2018 - "We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. "
01/01/2023 - "The effect of albiglutide on reducing the composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular events) was consistent with or without SGLT2 inhibitors (P interaction = 0.70). "
01/01/2021 - "Albiglutide was associated with fewer MACE and myocardial infarction events compared with lixisenatide. "

10/01/2022 - "In patients with T2D and cardiovascular disease, albiglutide appeared to have no effect in reducing HF-related events among patients with HF history. "
10/01/2022 - "Harmony Outcomes enrolled patients with T2D and cardiovascular disease randomized to either albiglutide or placebo over a median follow-up of 1.6 years. "
10/27/2018 - "Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial."
10/27/2018 - "In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. "
10/27/2018 - "We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. "

01/01/2017 - "Albiglutide caused weight reductions at a level comparable to placebo in the HARMONY trials, possibly related to limited central nervous system penetration of the large albiglutide molecule. "
01/01/2015 - "Albiglutide did not cause significant weight loss compared to placebo, but the adverse events profile was favorable with gastrointestinal adverse events occurring only slightly more with albiglutide than placebo. "
10/01/2009 - "Weight loss (-1.1 to -1.7 kg) was observed with these three albiglutide doses with no significant between-group effects. "
10/01/2009 - "Weekly albiglutide administration significantly improved glycemic control and elicited weight loss in type 2 diabetic patients, with a favorable safety and tolerability profile."
11/01/2017 - "In the Latino/Hispanic population, albiglutide resulted in effective lowering of glucose and modest weight loss, and it was generally well tolerated."